Please login to the form below

Not currently logged in

Lack of treatments depress EU bladder cancer market

Lack of treatments are depressing the EU bladder cancer market according to a Frost & Sullivan report

Lack of successful treatments are depressing the EU bladder cancer market According to a Frost & Sullivan report.

Patients are still dying from muscle invasive disease, despite aggressive therapy. The report reveals that median survival after chemotherapy is usually 14 months. Moreover, no new drugs have entered the market over the past two decades, which has limited the scope for newer and more effective bladder cancer therapeutics. Research results remain disappointing.

The report, entitled European Bladder Cancer Therapeutics Markets, says that the market racked up revenue of USD 128.3m in 2006 and estimates it could increase to USD 163.2m in 2013.

Frost & Sullivan Programme Leader, Paljit Mudhar, said: "There is a clear medical need for enhanced treatment options to manage the disease, as five-year survival rates in patients receiving conventional systemic therapy for metastatic disease are poor. There is a huge unmet need for novel drug delivery treatments which improve survival or increase the therapeutic ratio of systemic therapy."

Products currently in the pipeline for bladder cancer are unlikely to dramatically change the competitive landscape over the long term, as they do not offer substantial improvement or change compared with existing treatments. As a result of limited products in the pipeline in the phase III stage, the compound annual growth rate (CAGR) for the market is low.

Table 1: Current pipeline for bladder cancer

Drug Name Class Developer Phase
572016 ErbB-2 and EGFR dual kinase inhibitor GlaxoSmithKline III
Advexin (adenoviral p53) Gene therapy Introgen Therapeutics, NCI I
Alimta (pemetrexed sodium) Multi-targeted antifolate Eli Lilly II
Bexidem Macrophage IDM II/III
Celebrex (celecoxib) COX inhibitor Pfizer III
CG8840 Oncolytic virus Cell Genesys Pre-clinical
Eflornithine (difluoromethylornithine) Ornithine decarboxylase inhibitor Ilex Oncology Genzyme III
Eoquin (apezequone) Bioreductive prodrug Spectrum Pharmaceuticals I
Fenretinide Vitamin A analogue NCI III
Gallium maltolate Gallium (semi-metalic) Titan Pharmaceuticals I/II
Hexvix Photosensitizing agent PhotoCure ASA III
Levulan PD Photodynamic therapy DUSA Pharmaceuticals II
MCC (urocidin) Mycobacterial cell wall-DNA complex Bioniche Life Sciences III
Suramin Anti-angiogenic NCI I/II
Tempostatin (halafuginone hydrobromide) Extracellular matrix protein inhibitor Collgard Pharmaceuticals II
TOCOSOL Paclitaxel (S-8184) Taxane Sonus Pharmaceuticals II

In the meantime, numerous challenges threaten market growth, including development issues as a result of a lack of drugs that consistently prevent disease recurrence and progression. Also, the high cost of bladder cancer treatment is placing intense pressure on healthcare providers, because costs associated with bladder cancer treatment are higher than that of other cancers since it tends to be a lifelong disease.

"The European bladder cancer therapeutics market is likely to be considerably impacted from 2013 onwards, when monoclonal antibody treatments, such as GlaxoSmithKline's Tykerb (lapatinib) are likely to enter the market for this indication. Growth in the market will be determined primarily by the acceptance and uptake rates. Higher drug values within targeted therapy areas will be reflected in increased market revenues," concluded Mudhar.

For more information click here.

30th September 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...